Triptorelin
A long-acting synthetic GnRH agonist that is FDA-approved for hormonal suppression, but whose brief initial LH/FSH flare drives its off-label reputation as a single-shot HPG-axis restart.
Triptorelin is a synthetic decapeptide GnRH agonist with a D-tryptophan substitution at position 6 that resists peptidase degradation and extends its half-life far beyond native GnRH. Continuous or depot administration paradoxically desensitizes pituitary GnRH receptors, suppressing LH, FSH, and sex hormones to castrate levels — the basis of its approved use in advanced prostate cancer, central precocious puberty, endometriosis, and uterine fibroids. Community interest instead targets the opposite end of its biphasic action: the brief initial LH/FSH flare, discussed off-label as a post-cycle HPG-axis restart, though that use rests on case-report-level evidence.
Class
Synthetic decapeptide (GnRH agonist, D-Trp6 substitution)
Half-life
~3 hours plasma half-life for the immediate-release form; depot formulations provide sustained release over 1-6 months depending on preparation.
Routes
Subcutaneous, Intramuscular, Intramuscular depot
Category
Hormone & Reproductive
Researched benefits
What it's studied for
Androgen deprivation for prostate cancer
Chronic depot dosing drives testosterone to castrate levels via pituitary GnRH-receptor downregulation, forming the basis of standard-of-care androgen deprivation therapy for advanced prostate cancer with decades of clinical evidence.
Central precocious puberty control
Sustained GnRH-axis suppression halts premature pubertal progression; a phase III study of the 6-month formulation achieved pre-pubertal LH suppression in 93-98% of treated children and slowed bone maturation.
Endometriosis and uterine fibroid management
By suppressing ovarian sex-hormone output, triptorelin (Decapeptyl) is used internationally to shrink hormone-dependent gynecologic tissue and control associated symptoms.
Oocyte maturation trigger in IVF/ICSI
A single triptorelin dose can trigger final oocyte maturation in assisted-reproduction protocols; in freeze-all IVF it produced embryological outcomes comparable to GnRH-antagonist cycles.
HPG-axis restart (off-label, investigational)
The brief initial LH/FSH flare before receptor downregulation is the mechanistic rationale for a single low-dose restart of endogenous testosterone after anabolic steroid use, though the supporting evidence is limited to a single case report.
Mechanism
How it works
Triptorelin is a decapeptide analog of gonadotropin-releasing hormone (GnRH) in which a D-tryptophan is substituted at position 6. This substitution resists enzymatic degradation, extending the half-life from the minutes of native GnRH to several hours and increasing receptor-binding potency.
Its action on the hypothalamic-pituitary-gonadal (HPG) axis is biphasic. An initial dose acutely stimulates pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the 'flare' — which transiently raises sex steroids. This flare window lasts roughly 48-72 hours before receptor dynamics change.
With continuous or depot exposure, the constant receptor occupancy desensitizes and downregulates pituitary GnRH receptors, collapsing LH and FSH output and driving testosterone or estrogen to castrate levels. This sustained suppression — sometimes called medical castration — is the effect approved clinical use relies on for prostate cancer, precocious puberty, and gynecologic conditions.
The off-label restart rationale inverts this: rather than the suppression phase, it aims to harvest only the initial flare from a single low dose, hoping the intense LH/FSH pulse re-sensitizes an axis blunted by prolonged exogenous androgens. Because the same molecule produces sustained suppression with repeated or incorrect dosing, the wrong protocol achieves the opposite of the intended restart.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Approved depot formulations (Trelstar, Triptodur) are supplied as clinician-administered sustained-release injections and are not user-reconstituted. Research-grade lyophilized triptorelin is reconstituted with bacteriostatic water; consult a reconstitution calculator to convert vial size and diluent volume into draw volume.
Clinical (prostate cancer, depot)
- Dose
- 22.5 mg (6-month embonate formulation); other depots dose 1-3 months
- Frequency
- Every 24 weeks (6-month depot) or per formulation interval
- Timing
- Per clinical schedule under specialist supervision
- Duration
- Ongoing per treatment plan
- Route
- Intramuscular depot
6-month embonate shows testosterone-suppression efficacy comparable to the 3-month preparation. Anti-androgen coverage is often used to manage the initial flare.
Clinical (central precocious puberty)
- Dose
- 22.5 mg (6-month formulation)
- Frequency
- Every 24 weeks
- Timing
- Per pediatric endocrinology schedule
- Duration
- Until appropriate age to resume puberty
- Route
- Intramuscular
Achieved pre-pubertal LH suppression in ~93% at month 6 and ~98% at month 12 in a phase III study; requires specialist monitoring.
Off-label restart (case-report, investigational)
- Dose
- 100 mcg single test dose
- Frequency
- Single administration
- Timing
- After an anabolic androgen cycle, in a suppressed-axis context
- Duration
- One-time (with recovery assessed over ~1 month)
- Route
- Subcutaneous or intramuscular
Traces to Pirola et al. 2010 — one 34-year-old man, one 100 mcg dose, recovery over one month. This is a mechanistic anecdote, not a validated protocol; repeated or higher dosing risks the suppression phase instead of recovery.
- Approved use is specialist-supervised depot injection; monitoring is required for the initial hormonal flare and for the physiological effects of prolonged sex-hormone suppression.
- The off-label single-shot restart depends on a narrow ~48-72 hour flare window; incorrect or repeated dosing produces sustained suppression — the opposite of the intended effect.
- HCG plus a SERM (clomiphene or tamoxifen) remains the better-characterized historical post-cycle approach; head-to-head evidence versus triptorelin is non-existent.
- WADA bans GnRH agonists including triptorelin at all times for male athletes — a regulatory consideration separate from the pharmacology.
Evidence
Research & clinical studies (6)
GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis
Across 20 RCTs (2,400 PCOS patients), triptorelin ranked third of five GnRH agents for clinical pregnancy rate (47.9%) and second for live birth rate (44.1%), but lowest for reducing ovarian hyperstimulation syndrome (15.7%).
PMID 42152207Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty
In 44 treatment-naive children, triptorelin 22.5 mg IM every 24 weeks achieved pre-pubertal LH suppression in 93.2% at month 6 and 97.7% at month 12 with no unexpected adverse events.
PMID 26887034Efficacy of the 3-month formulation of triptorelin in children with idiopathic central precocious puberty
The 3-month formulation effectively suppressed hormone levels and slowed bone maturation over a 12-month period with good tolerability and no discontinuations for adverse effects.
PMID 42130352Triptorelin embonate: a 6-month formulation for prostate cancer
Reviews triptorelin embonate 22.5 mg as a 6-month LHRH agonist, documenting testosterone-suppression efficacy and safety comparable to the 3-month preparation across prostate cancer, endometriosis, fibroids, and precocious puberty.
PMID 20969451Outcomes of GnRH agonist trigger in dydrogesterone-based PPOS versus GnRH antagonist cycles: a retrospective parallel cohort in freeze-all IVF treatment
Using triptorelin as the final oocyte-maturation trigger, dydrogesterone-based PPOS produced laboratory and embryological outcomes comparable to GnRH-antagonist cycles in freeze-all IVF.
PMID 41980430Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report
A prolonged triptorelin-based GnRH agonist protocol achieved a successful pregnancy in a 41-year-old woman with adenomyosis, endometriosis, and male-factor infertility.
PMID 42199947Combinations
Stacking & blends
Anti-androgen flare coverage
Prevent disease flare during prostate cancer ADT
The initial LH/FSH flare transiently raises testosterone and can worsen prostate cancer symptoms; anti-androgen coverage during initiation blunts the surge until suppression takes hold.
Historical PCT comparison (context, not a co-administration)
HPG-axis recovery after anabolic steroid use
HCG plus a SERM is the better-characterized historical post-cycle approach in the literature and is the standard against which off-label single-shot triptorelin restart is compared; head-to-head data are absent.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Hormone-sensitive cancers (depot form, without oncology supervision)
- Ongoing testosterone replacement therapy
- Active hormonal therapy
- Male athletes subject to WADA testing (prohibited at all times)
Approved use requires specialist supervision for the initial flare and the physiological consequences of prolonged sex-hormone suppression. Repeated single-dose restart cycling in healthy men has not been specifically studied; theoretical risks of pituitary desensitization with repeated acute exposure are plausible but unquantified. Incorrect dosing for restart purposes can produce the suppression the user is trying to avoid.
FAQ
Triptorelin — common questions
What is triptorelin?
Triptorelin is a long-acting synthetic GnRH agonist — a decapeptide with a D-tryptophan substitution at position 6 that extends its half-life well beyond native GnRH. It is FDA-approved as Trelstar for advanced prostate cancer and as Triptodur for central precocious puberty, and approved internationally as Decapeptyl for endometriosis and uterine fibroids.
What does triptorelin do?
It has a biphasic effect on the HPG axis. Initial dosing causes a brief surge in LH and testosterone (the flare); continued or depot dosing desensitizes pituitary GnRH receptors and suppresses testosterone to castrate levels. Clinical use relies on the suppression phase, while post-cycle forums try to harvest the initial surge.
Can triptorelin restart the HPG axis after a steroid cycle?
This off-label idea rests on a single case report — Pirola et al. 2010, one 34-year-old man given a single 100 mcg dose with recovery over one month. It is a mechanistic anecdote, not a validated protocol, and community regimens often stretch far beyond that evidence. Used wrong, the drug's suppression phase is the result rather than recovery.
How is triptorelin administered?
FDA-approved use is intramuscular depot injection under clinician supervision for sustained suppression in prostate cancer or precocious puberty, with formulations covering 1-, 3-, and 6-month intervals. Off-label restart use is non-depot and covered by neither FDA label.
Is triptorelin FDA approved?
Yes — as Trelstar for advanced prostate cancer (2000) and as Triptodur for central precocious puberty, plus international approval as Decapeptyl for gynecologic and oncology indications. All PCT/restart use is off-label.
Is triptorelin allowed in sport?
No. WADA prohibits GnRH agonists, including triptorelin, at all times for male athletes. This regulatory prohibition is separate from and additional to the pharmacological considerations.
How does it compare to HCG-based PCT?
HCG plus a SERM (clomiphene or tamoxifen) has a far larger real-world track record for post-cycle recovery, and there is no head-to-head evidence establishing triptorelin as superior. The single-shot triptorelin approach relies on a narrow flare window and case-report-level data.
